Skip to main content
SpringerLink
Log in

Genomic Analysis of B-Cell Lymphomas

  • Chapter
  • First Online:
Book cover Lymphoma

Part of the book series: Current Clinical Oncology ((CCO,volume 43))

  • 2450 Accesses

Abstract

Technical progress has enabled molecular analysis of lymphoma samples on a genomic scale. Research on many fronts is now providing a comprehensive picture of the lymphoma cell’s genomic sequence, identifying its mutations and allelic derangements, and the epigenetic regulation and transcription of that genome. Macromolecules of other types are also being profiled, including noncoding RNA, proteins, and other non-nucleic acid metabolites. Furthermore, whether by design or inadvertent inclusion, elements in the tumor microenvironment are often included and provide important insights into key processes such as angiogenesis, stromal reaction, and interaction with the host immune system. The wealth of data generated by these studies also brings challenges in interpretation, for which a variety of analytical techniques are used. This chapter selectively covers the development and current status of genomic analyses of B-cell lymphomas, some of the prominent findings, and the prospects for clinical application.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Obermann EC, Csato M, Dirnhofer S, Tzankov A. BCL2 gene aberration as an IPI-independent marker for poor outcome in non-germinal-centre diffuse large B cell lymphoma. J Clin Pathol. 2009;62:903–7.

    Article  PubMed  CAS  Google Scholar 

  2. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403:503–11.

    Article  PubMed  CAS  Google Scholar 

  3. Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:1937–47.

    Article  PubMed  Google Scholar 

  4. Lenz G, Wright G, Dave SS, Xiao W, Powell J, Zhao H, et al. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med. 2008;359:2313–23.

    Article  PubMed  CAS  Google Scholar 

  5. Lenz G, Wright GW, Emre NC, Kohlhammer H, Dave SS, Davis RE, et al. Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc Natl Acad Sci USA. 2008;105:13520–5.

    Article  PubMed  CAS  Google Scholar 

  6. Lenz G, Staudt LM. Aggressive lymphomas. N Engl J Med. 2010;362:1417–29.

    Article  PubMed  CAS  Google Scholar 

  7. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B. 1995;57:289–300.

    Google Scholar 

  8. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA. 2001;98:5116–21.

    Article  PubMed  CAS  Google Scholar 

  9. Wright G, Tan B, Rosenwald A, Hurt EH, Wiestner A, Staudt LM. A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci USA. 2003;100:9991–6.

    Article  PubMed  CAS  Google Scholar 

  10. Dave SS, Wright G, Tan B, Rosenwald A, Gascoyne RD, Chan WC, et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med. 2004;351:2159–69.

    Article  PubMed  CAS  Google Scholar 

  11. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 2005;102:15545–50.

    Article  PubMed  CAS  Google Scholar 

  12. Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, Wrobel MJ, et al. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science. 2006;313:1929–35.

    Article  PubMed  CAS  Google Scholar 

  13. Davis RE, Brown KD, Siebenlist U, Staudt LM. Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med. 2001;194:1861–74.

    Article  PubMed  CAS  Google Scholar 

  14. Ngo VN, Davis RE, Lamy L, Yu X, Zhao H, Lenz G, et al. A loss-of-function RNA interference screen for molecular targets in cancer. Nature. 2006;441:106–10.

    Article  PubMed  CAS  Google Scholar 

  15. Lenz G, Davis RE, Ngo VN, Lam L, George TC, Wright GW, et al. Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. Science. 2008;319:1676–9.

    Article  PubMed  CAS  Google Scholar 

  16. Davis RE, Ngo VN, Lenz G, Tolar P, Young R, Romesser PB, et al. Chronic active B cell receptor signaling in diffuse large B cell lymphoma. Nature. 2010;463:88–92.

    Article  PubMed  CAS  Google Scholar 

  17. Ngo VN, Young RM, Schmitz R, Jhavar S, Xiao W, Lim KH, et al. Oncogenically active MYD88 mutations in human lymphoma. Nature. 2011;470(7332):115–9.

    Article  PubMed  CAS  Google Scholar 

  18. Honigberg LA, Smith AM, Sirisawada M, Vernera E, Lourya D, Changa B, et al. The Btk inhibitor PCI-32765 blocks B cell activation and is efficacious in models of autoimmune disease and B cell malignancy. Proc Natl Acad Sci USA. 2010;107:13075–80.

    Article  PubMed  CAS  Google Scholar 

  19. Dunleavy K, Pittaluga S, Czuczman MS, Dave SS, Wright G, Grant N, et al. Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. Blood. 2009;113:6069–76.

    Article  PubMed  CAS  Google Scholar 

  20. Cerchietti LC, Ghetu AF, Zhu X, Da Silva GF, Zhong S, Matthews M, et al. A small-molecule inhibitor of BCL6 kills DLBCL cells in vitro and in vivo. Cancer Cell. 2010;17:400–11. 2858395.

    Article  PubMed  CAS  Google Scholar 

  21. Scuto A, Kujawski M, Kowolik C, Krymskaya L, Wang L, Weiss LM, et al. STAT3 inhibition is a therapeutic strategy for ABC-like diffuse large B-cell lymphoma. Cancer Res. 2011;71:3182–8. 3085657.

    Article  PubMed  CAS  Google Scholar 

  22. Kloo B, Nagel D, Pfeifer M, Grau M, Duwel M, Vincendeau M, et al. Critical role of PI3K signaling for NF-kappaB-dependent survival in a subset of activated B-cell-like diffuse large B-cell lymphoma cells. Proc Natl Acad Sci USA. 2011;108:272–7. 3017191.

    Article  PubMed  CAS  Google Scholar 

  23. Zhao MY, Auerbach A, D’Costa AM, Rapoport AP, Burger AM, Sausville EA, et al. Phospho-p70S6K/p85S6K and cdc2/cdk1 are novel targets for diffuse large B-cell lymphoma combination therapy. Clin Cancer Res. 2009;15:1708–20.

    Article  PubMed  CAS  Google Scholar 

  24. Velichutina I, Shaknovich R, Geng H, Johnson NA, Gascoyne RD, Melnick AM, et al. EZH2-mediated epigenetic silencing in germinal center B cells contributes to proliferation and lymphomagenesis. Blood. 2010;116:5247–55. 3012542.

    Article  PubMed  CAS  Google Scholar 

  25. Blenk S, Engelmann J, Weniger M, Schultz J, Dittrich M, Rosenwald A, et al. Germinal center B cell-like (GCB) and activated B cell-like (ABC) type of diffuse large B cell lymphoma (DLBCL): analysis of molecular predictors, signatures, cell cycle state and patient survival. Cancer Inform. 2007;3:399–420. 2675856.

    PubMed  CAS  Google Scholar 

  26. Malumbres R, Chen J, Tibshirani R, Johnson NA, Sehn LH, Natkunam Y, et al. Paraffin-based 6-gene model predicts outcome in diffuse large B-cell lymphoma patients treated with R-CHOP. Blood. 2008;111:5509–14. 2424149.

    Article  PubMed  CAS  Google Scholar 

  27. Alizadeh AA, Gentles AJ, Alencar AJ, Liu CL, Kohrt HE, Houot R, et al. Prediction of survival in diffuse large B-cell lymphoma based on the expression of 2 genes reflecting tumor and microenvironment. Blood. 2011;118:1350–8. 3152499.

    Article  PubMed  CAS  Google Scholar 

  28. Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103:275–82.

    Article  PubMed  CAS  Google Scholar 

  29. Choi WW, Weisenburger DD, Greiner TC, Piris MA, Banham AH, Delabie J, et al. A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. Clin Cancer Res. 2009;15:5494–502.

    Article  PubMed  CAS  Google Scholar 

  30. Salles G, de Jong D, Xie W, Rosenwald A, Chhanabhai M, Gaulard P, et al. Prognostic significance of immunohistochemical biomarkers in diffuse large B-cell lymphoma: a study from the Lunenburg Lymphoma Biomarker Consortium. Blood. 2011;117:7070–8.

    Article  PubMed  CAS  Google Scholar 

  31. Rimsza LM, Leblanc ML, Unger JM, Miller TP, Grogan TM, Persky DO, et al. Gene expression predicts overall survival in paraffin-embedded tissues of diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2008;112:3425–33.

    Article  PubMed  CAS  Google Scholar 

  32. Kulkarni MM. Digital multiplexed gene expression analysis using the NanoString nCounter system. Curr Protoc Mol Biol. 2011. doi:10.1002/0471142727.mb25b10s94. Chapter 25, Unit25B 10.

  33. Tzankov A, Zlobec I, Went P, Robl H, Hoeller S, Dirnhofer S. Prognostic immunophenotypic biomarker studies in diffuse large B cell lymphoma with special emphasis on rational determination of cut-off scores. Leuk Lymphoma. 2010;51:199–212.

    Article  PubMed  CAS  Google Scholar 

  34. Rosenwald A, Wright G, Leroy K, Yu X, Gaulard P, Gascoyne RD, et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med. 2003;198:851–62. 2194208.

    Article  PubMed  CAS  Google Scholar 

  35. Bertucci F, Chetaille B, Xerri L. Gene expression profiling for in silico microdissection of Hodgkin’s lymphoma microenvironment and identification of prognostic features. Adv Hematol. 2011;2011:485310. 3004394.

    PubMed  Google Scholar 

  36. Sanchez-Espiridion B, Montalban C, Lopez A, Menarguez J, Sabin P, Ruiz-Marcellan C, et al. A molecular risk score based on 4 functional pathways for advanced classical Hodgkin lymphoma. Blood. 2010;116:e12–7.

    Article  PubMed  CAS  Google Scholar 

  37. Derenzini E, Younes A. Predicting treatment outcome in classical Hodgkin lymphoma: genomic advances. Genome Med. 2011;3:26. 3129642.

    Article  PubMed  CAS  Google Scholar 

  38. Steidl C, Lee T, Shah SP, Farinha P, Han G, Nayar T, et al. Tumor-associated macrophages and survival in classic Hodgkin’s lymphoma. N Engl J Med. 2010;362:875–85. 2897174.

    Article  PubMed  CAS  Google Scholar 

  39. Brune V, Tiacci E, Pfeil I, Doring C, Eckerle S, van Noesel CJ, et al. Origin and pathogenesis of nodular lymphocyte-predominant Hodgkin lymphoma as revealed by global gene expression analysis. J Exp Med. 2008;205:2251–68. 2556780.

    Article  PubMed  CAS  Google Scholar 

  40. Farinha P, Al-Tourah A, Gill K, Klasa R, Connors JM, Gascoyne RD. The architectural pattern of FOXP3-positive T cells in follicular lymphoma is an independent predictor of survival and histologic transformation. Blood. 2010;115:289–95.

    Article  PubMed  CAS  Google Scholar 

  41. Kelley T, Beck R, Absi A, Jin T, Pohlman B, Hsi E. Biologic predictors in follicular lymphoma: importance of markers of immune response. Leuk Lymphoma. 2007;48:2403–11.

    Article  PubMed  Google Scholar 

  42. Cerhan JR, Wang S, Maurer MJ, Ansell SM, Geyer SM, Cozen W, et al. Prognostic significance of host immune gene polymorphisms in follicular lymphoma survival. Blood. 2007;109:5439–46.

    Article  PubMed  CAS  Google Scholar 

  43. Bryant PA, Smyth GK, Robins-Browne R, Curtis N. Detection of gene expression in an individual cell type within a cell mixture using microarray analysis. PLoS One. 2009;4:e4427.

    Article  PubMed  CAS  Google Scholar 

  44. Pangault C, Ame-Thomas P, Ruminy P, Rossille D, Caron G, Baia M, et al. Follicular lymphoma cell niche: identification of a preeminent IL-4-dependent T(FH)-B cell axis. Leukemia. 2010;24:2080–9.

    Article  PubMed  CAS  Google Scholar 

  45. Rosenwald A, Wright G, Wiestner A, Chan WC, Connors JM, Campo E, et al. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell. 2003;3:185–97.

    Article  PubMed  CAS  Google Scholar 

  46. Wiestner A, Tehrani M, Chiorazzi M, Wright G, Gibellini F, Nakayama K, et al. Point mutations and genomic deletions in CCND1 create stable truncated cyclin D1 mRNAs that are associated with increased proliferation rate and shorter survival. Blood. 2007;109:4599–606. 1885523.

    Article  PubMed  CAS  Google Scholar 

  47. Mozos A, Royo C, Hartmann E, De Jong D, Baro C, Valera A, et al. SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype. Haematologica. 2009;94:1555–62. 2770966.

    Article  PubMed  CAS  Google Scholar 

  48. Fernandez V, Salamero O, Espinet B, Sole F, Royo C, Navarro A, et al. Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma. Cancer Res. 2010;70:1408–18.

    Article  PubMed  CAS  Google Scholar 

  49. Hartmann EM, Campo E, Wright G, Lenz G, Salaverria I, Jares P, et al. Pathway discovery in mantle cell lymphoma by integrated analysis of high-resolution gene expression and copy number profiling. Blood. 2010;116:953–61. 2924229.

    Article  PubMed  CAS  Google Scholar 

  50. Dave SS, Fu K, Wright GW, Lam LT, Kluin P, Boerma EJ, et al. Molecular diagnosis of Burkitt’s lymphoma. N Engl J Med. 2006;354:2431–42.

    Article  PubMed  CAS  Google Scholar 

  51. Piccaluga PP, De Falco G, Kustagi M, Gazzola A, Agostinelli C, Tripodo C, et al. Gene expression analysis uncovers similarity and differences among Burkitt lymphoma subtypes. Blood. 2010;117:3596–608.

    Article  CAS  Google Scholar 

  52. Garber M, Grabherr MG, Guttman M, Trapnell C. Computational methods for transcriptome annotation and quantification using RNA-seq. Nat Methods. 2011;8:469–77.

    Article  PubMed  CAS  Google Scholar 

  53. Malone JH, Oliver B. Microarrays, deep sequencing and the true measure of the transcriptome. BMC Biol. 2011;9:34. 3104486.

    Article  PubMed  CAS  Google Scholar 

  54. Greenman C, Wooster R, Futreal PA, Stratton MR, Easton DF. Statistical analysis of pathogenicity of somatic mutations in cancer. Genetics. 2006;173:2187–98. 1569711.

    Article  PubMed  CAS  Google Scholar 

  55. Pasqualucci L, Trifonov V, Fabbri G, Ma J, Rossi D, Chiarenza A, et al. Analysis of the coding genome of diffuse large B-cell lymphoma. Nat Genet. 2011;43:830–7.

    Article  PubMed  CAS  Google Scholar 

  56. Morin RD, Mendez-Lago M, Mungall AJ, Goya R, Mungall KL, Corbett RD, et al. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature. 2011;476:298–303. 3210554.

    Article  PubMed  CAS  Google Scholar 

  57. Morin RD, Johnson NA, Severson TM, Mungall AJ, An J, Goya R, et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet. 2010;42:181–5. 2850970.

    Article  PubMed  CAS  Google Scholar 

  58. Yap DB, Chu J, Berg T, Schapira M, Cheng SW, Moradian A, et al. Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation. Blood. 2011;117:2451–9. 3062411.

    Article  PubMed  CAS  Google Scholar 

  59. Sneeringer CJ, Scott MP, Kuntz KW, Knutson SK, Pollock RM, Richon VM, et al. Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas. Proc Natl Acad Sci USA. 2010;107:20980–5. 3000297.

    Article  PubMed  CAS  Google Scholar 

  60. Compagno M, Lim WK, Grunn A, Nandula SV, Brahmachary M, Shen Q, et al. Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. Nature. 2009;459:717–21. 2973325.

    Article  PubMed  CAS  Google Scholar 

  61. Calado DP, Zhang B, Srinivasan L, Sasaki Y, Seagal J, Unitt C, et al. Constitutive canonical NF-kappaB activation cooperates with disruption of BLIMP1 in the pathogenesis of activated B cell-like diffuse large cell lymphoma. Cancer Cell. 2010;18:580–9. 3018685.

    Article  PubMed  CAS  Google Scholar 

  62. Roddam PL, Allan JM, Dring AM, Worrillow LJ, Davies FE, Morgan GJ. Non-homologous end-joining gene profiling reveals distinct expression patterns associated with lymphoma and multiple myeloma. Br J Haematol. 2010;149:258–62.

    Article  PubMed  CAS  Google Scholar 

  63. Gruber TA, Chang MS, Sposto R, Muschen M. Activation-induced cytidine deaminase accelerates clonal evolution in BCR-ABL1-driven B-cell lineage acute lymphoblastic leukemia. Cancer Res. 2010;70:7411–20. 2948648.

    Article  PubMed  CAS  Google Scholar 

  64. Rui L, Emre NC, Kruhlak MJ, Chung HJ, Steidl C, Slack G, et al. Cooperative epigenetic modulation by cancer amplicon genes. Cancer Cell. 2010;18:590–605. 3049192.

    Article  PubMed  CAS  Google Scholar 

  65. Green MR, Monti S, Rodig SJ, Juszczynski P, Currie T, O’Donnell E, et al. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood. 2010;116:3268–77. 2995356.

    Article  PubMed  CAS  Google Scholar 

  66. Cheung KJ, Johnson NA, Affleck JG, Severson T, Steidl C, Ben-Neriah S, et al. Acquired TNFRSF14 mutations in follicular lymphoma are associated with worse prognosis. Cancer Res. 2010;70:9166–74.

    Article  PubMed  CAS  Google Scholar 

  67. Akavia UD, Litvin O, Kim J, Sanchez-Garcia F, Kotliar D, Causton HC, et al. An integrated approach to uncover drivers of cancer. Cell. 2010;143:1005–17. 3013278.

    Article  PubMed  CAS  Google Scholar 

  68. Green MR, Aya-Bonilla C, Gandhi MK, Lea RA, Wellwood J, Wood P, et al. Integrative genomic profiling reveals conserved genetic mechanisms for tumorigenesis in common entities of non-Hodgkin’s lymphoma. Genes Chromosomes Cancer. 2011;50:313–26.

    Article  PubMed  CAS  Google Scholar 

  69. Malumbres R, Sarosiek KA, Cubedo E, Ruiz JW, Jiang X, Gascoyne RD, et al. Differentiation stage-specific expression of microRNAs in B lymphocytes and diffuse large B-cell lymphomas. Blood. 2009;113:3754–64.

    Article  PubMed  CAS  Google Scholar 

  70. Zhang J, Jima DD, Jacobs C, Fischer R, Gottwein E, Huang G, et al. Patterns of microRNA expression characterize stages of human B-cell differentiation. Blood. 2009;113:4586–94.

    Article  PubMed  CAS  Google Scholar 

  71. Montes-Moreno S, Martinez N, Sanchez-Espiridion B, Diaz Uriarte R, Rodriguez ME, Saez A, et al. miRNA expression in diffuse large B-cell lymphoma treated with chemoimmunotherapy. Blood. 2011;118:1034–40.

    Article  PubMed  CAS  Google Scholar 

  72. Di Lisio L, Gomez-Lopez G, Sanchez-Beato M, Gomez-Abad C, Rodriguez ME, Villuendas R, et al. Mantle cell lymphoma: transcriptional regulation by microRNAs. Leukemia. 2010;24:1335–42.

    Article  PubMed  CAS  Google Scholar 

  73. Jima DD, Zhang J, Jacobs C, Richards KL, Dunphy CH, Choi WW, et al. Deep sequencing of the small RNA transcriptome of normal and malignant human B cells identifies hundreds of novel microRNAs. Blood. 2010;116:e118–27. 3012600.

    Article  PubMed  CAS  Google Scholar 

  74. Ma L, Reinhardt F, Pan E, Soutschek J, Bhat B, Marcusson EG, et al. Therapeutic silencing of miR-10b inhibits metastasis in a mouse mammary tumor model. Nat Biotechnol. 2010;28:341–7. 2852471.

    Article  PubMed  CAS  Google Scholar 

  75. Valastyan S, Chang A, Benaich N, Reinhardt F, Weinberg RA. Activation of miR-31 function in already-established metastases elicits metastatic regression. Genes Dev. 2011;25:646–59. 3059837.

    Article  PubMed  CAS  Google Scholar 

  76. Choi JH, Li Y, Guo J, Pei L, Rauch TA, Kramer RS, et al. Genome-wide DNA methylation maps in follicular lymphoma cells determined by methylation-enriched bisulfite sequencing. PLoS One. 2010;5(9):e13020. 2947499.

    Article  PubMed  CAS  Google Scholar 

  77. Shi H, Guo J, Duff DJ, Rahmatpanah F, Chitima-Matsiga R, Al-Kuhlani M, et al. Discovery of novel epigenetic markers in non-Hodgkin’s lymphoma. Carcinogenesis. 2007;28:60–70.

    Article  PubMed  CAS  Google Scholar 

  78. Shaknovich R, Geng H, Johnson NA, Tsikitas L, Cerchietti L, Greally JM, et al. DNA methylation signatures define molecular subtypes of diffuse large B-cell lymphoma. Blood. 2010;116:e81–9. 2993635.

    Article  PubMed  CAS  Google Scholar 

  79. Eberle FC, Rodriguez-Canales J, Wei L, Hanson JC, Killian JK, Sun HW, et al. Methylation profiling of mediastinal gray zone lymphoma reveals a distinctive signature with elements shared by classical Hodgkin’s lymphoma and primary mediastinal large B-cell lymphoma. Haematologica. 2011;96:558–66. 3069233.

    Article  PubMed  Google Scholar 

  80. Leshchenko VV, Kuo PY, Shaknovich R, Yang DT, Gellen T, Petrich A, et al. Genomewide DNA methylation analysis reveals novel targets for drug development in mantle cell lymphoma. Blood. 2010;116:1025–34. 2938124.

    Article  PubMed  CAS  Google Scholar 

  81. Enjuanes A, Fernandez V, Hernandez L, Navarro A, Bea S, Pinyol M, et al. Identification of methylated genes associated with aggressive clinicopathological features in mantle cell lymphoma. PLoS One. 2011;6:e19736. 3095614.

    Article  PubMed  CAS  Google Scholar 

  82. Hasselblom S, Hansson U, Olsson M, Toren L, Bergstrom A, Nilsson-Ehle H, et al. High immunohistochemical expression of p-AKT predicts inferior survival in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Br J Haematol. 2010;149:560–8.

    Article  PubMed  CAS  Google Scholar 

  83. Mactier S, Henrich S, Che Y, Kohnke PL, Christopherson RI. Comprehensive proteomic analysis of the effects of purine analogs on human Raji B-cell lymphoma. J Proteome Res. 2011;10:1030–42.

    Article  PubMed  CAS  Google Scholar 

  84. Jiang Y, Liu X, Fang X, Wang X. Proteomic analysis of mitochondria in Raji cells following exposure to radiation: implications for radiotherapy response. Protein Pept Lett. 2009;16:1350–9.

    Article  PubMed  CAS  Google Scholar 

  85. Fagerberg L, Stromberg S, El-Obeid A, Gry M, Nilsson K, Uhlen M, et al. Large-scale protein profiling in human cell lines using antibody-based proteomics. J Proteome Res. 2011;10:4066–75.

    Article  PubMed  CAS  Google Scholar 

  86. Carter BZ, Qiu YH, Zhang N, Coombes KR, Mak DH, Thomas DA, et al. Expression of ARC (apoptosis repressor with caspase recruitment domain), an antiapoptotic protein, is strongly prognostic in AML. Blood. 2011;117:780–7. 3035072.

    Article  PubMed  CAS  Google Scholar 

  87. Creighton CJ, Fu X, Hennessy BT, Casa AJ, Zhang Y, Gonzalez-Angulo AM, et al. Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer. Breast Cancer Res. 2010;12:R40. 2917035.

    Article  PubMed  CAS  Google Scholar 

  88. Boyd RS, Dyer MJ, Cain K. Proteomic analysis of B-cell malignancies. J Proteomics. 2010;73:1804–22.

    Article  PubMed  CAS  Google Scholar 

  89. Rolland D, Bouamrani A, Houlgatte R, Barbarat A, Ramus C, Arlotto M, et al. Identification of proteomic signatures of mantle cell lymphoma, small lymphocytic lymphoma, and marginal zone lymphoma biopsies by surface enhanced laser desorption/ionization-time of flight mass spectrometry. Leuk Lymphoma. 2011;52:648–58.

    Article  PubMed  CAS  Google Scholar 

  90. Pighi C, Gu TL, Dalai I, Barbi S, Parolini C, Bertolaso A, et al. Phospho-proteomic analysis of mantle cell lymphoma cells suggests a pro-survival role of B-cell receptor signaling. Cell Oncol (Dordr). 2011;34:141–53. 3063577.

    Article  CAS  Google Scholar 

  91. Kamper P, Ludvigsen M, Bendix K, Hamilton-Dutoit S, Rabinovich GA, Moller MB, et al. Proteomic analysis identifies galectin-1 as a predictive biomarker for relapsed/refractory disease in classical Hodgkin lymphoma. Blood. 2011;117:6638–49.

    Article  PubMed  CAS  Google Scholar 

  92. Juszczynski P, Ouyang J, Monti S, Rodig SJ, Takeyama K, Abramson J, et al. The AP1-dependent secretion of galectin-1 by Reed Sternberg cells fosters immune privilege in classical Hodgkin lymphoma. Proc Natl Acad Sci USA. 2007;104:13134–9. 1936978.

    Article  PubMed  CAS  Google Scholar 

  93. Kischel P, Waltregny D, Greffe Y, Mazzucchelli G, De Pauw E, de Leval L, et al. Identification of stromal proteins overexpressed in nodular sclerosis Hodgkin lymphoma. Proteome Sci. 2011;9:63. 3200160.

    Article  PubMed  CAS  Google Scholar 

  94. Schliemann C, Roesli C, Kamada H, Borgia B, Fugmann T, Klapper W, et al. In vivo biotinylation of the vasculature in B-cell lymphoma identifies BST-2 as a target for antibody-based therapy. Blood. 2011;115:736–44.

    Article  CAS  Google Scholar 

  95. Dang CV, Hamaker M, Sun P, Le A, Gao P. Therapeutic targeting of cancer cell metabolism. J Mol Med (Berl). 2011;89:205–12.

    Article  CAS  Google Scholar 

  96. Meynet O, Beneteau M, Jacquin MA, Pradelli LA, Cornille A, Carles M, et al. Glycolysis inhibition targets Mcl-1 to restore sensitivity of lymphoma cells to ABT-737-induced apoptosis. Leukemia. 2012;26(5):1145–7.

    PubMed  Google Scholar 

  97. Le A, Cooper CR, Gouw AM, Dinavahi R, Maitra A, Deck LM, et al. Inhibition of lactate dehydrogenase a induces oxidative stress and inhibits tumor progression. Proc Natl Acad Sci USA. 2011;107:2037–42. 2836706.

    Article  Google Scholar 

  98. Barba I, Sanz C, Barbera A, Tapia G, Mate JL, Garcia-Dorado D, et al. Metabolic fingerprinting of fresh lymphoma samples used to discriminate between follicular and diffuse large B-cell lymphomas. Exp Hematol. 2009;37:1259–65.

    Article  PubMed  CAS  Google Scholar 

  99. Bictash M, Ebbels TM, Chan Q, Loo RL, Yap IK, Brown IJ, et al. Opening up the “black box”: metabolic phenotyping and metabolome-wide association studies in epidemiology. J Clin Epidemiol. 2010;63:970–9.

    Article  PubMed  Google Scholar 

  100. Corona G, Rizzolio F, Giordano A, Toffoli G. Phamaco-metabolomics: an emerging “omics” tool for the personalization of anticancer treatments and identification of new valuable therapeutic targets. J Cell Physiol. 2012;227(7):2827–31.

    Article  PubMed  CAS  Google Scholar 

  101. Garcia-Manteiga JM, Mari S, Godejohann M, Spraul M, Napoli C, Cenci S, et al. Metabolomics of B to plasma cell differentiation. J Proteome Res. 2011;10:4165–76.

    Article  PubMed  CAS  Google Scholar 

  102. Barker AD, Sigman CC, Kelloff GJ, Hylton NM, Berry DA, Esserman LJ. I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clin Pharmacol Ther. 2009;86:97–100.

    Article  PubMed  CAS  Google Scholar 

  103. Jones D. Adaptive trials receive boost. Nat Rev Drug Discov. 2010;9:345–8.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, 7455 Fannin St, 77054, Houston, TX, USA

    R. Eric Davis MD

Authors
  1. R. Eric Davis MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to R. Eric Davis MD .

Editor information

Editors and Affiliations

  1. Holcombe Blvd. 1515, Houston, 77030, Texas, USA

    Anas Younes

  2. Service d'Hematologie, CHU Lyon-Sud, chemin du Grand Revoyet, Pierre Bénite, 69310, France

    Bertrand Coiffier

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Davis, R.E. (2013). Genomic Analysis of B-Cell Lymphomas. In: Younes, A., Coiffier, B. (eds) Lymphoma. Current Clinical Oncology, vol 43. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-62703-408-1_2

Download citation

  • DOI: https://doi.org/10.1007/978-1-62703-408-1_2

  • Published:

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-62703-407-4

  • Online ISBN: 978-1-62703-408-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation